At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 481 enrolled
Drug / intervention
Baloxavir Marboxildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle (pCHIMES)
In Brief
A Phase 4 clinical trial evaluating Baloxavir Marboxil for Influenza and Respiratory Viral Infection. Completed, enrolled 481 participants across 1 site.
Detailed Summary
This study will evaluate a home-based approach to influenza infection control, using prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery of Xofluza (Baloxavir marboxil) for administration within 48 hours of symptom onset.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Respiratory Viral Infection
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartNov 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedOct 28, 2019
Enrollment StartNov 1, 2019
Primary CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.7 years ago
Interventions
Baloxavir Marboxildrug
Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset